Limits...
Improvement of Experimentally Induced Hepatic and Renal Disorders in Rats using Lactic Acid Bacteria-fermented Soybean Extract (BiofermenticsTM).

Shin R, Suzuki M, Mizutani T, Susa N - Evid Based Complement Alternat Med (2007)

Bottom Line: In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of d-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF.Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group.These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

View Article: PubMed Central - PubMed

Affiliation: Central Institute for Health Science, A.L.A. Corporation 40-14 Kitamachi, Seya-ku, Yokohama-city, Kanagawa, 246-0002 Japan. rshin@ciala.co.jp.

ABSTRACT
The effects of lactic acid bacteria-fermented soybean extract (Biofermentics; BF) on experimental models of hepatic and renal disorders were investigated in vivo and in vitro. In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of d-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF. Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group. Pretreatment of primary cell cultures of rat hepatic and renal cells with BF prior to exposure to dichromate (K(2)Cr(2)O(7)) resulted in a marked decrease of dichromate-induced cytotoxicity as evaluated by the leakage of lactate dehydrogenase The levels of dichromate-induced lipid peroxidation, as monitored by malondialdehyde formation, were also reduced by pretreatment of hepatocytes with BF. These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

No MeSH data available.


Related in: MedlinePlus

Effects of oral BF administration on serum AST (A) and ALT (B) activities in rats with hepatic disorders induced by DCA loading. The DCA control group (open square) was given MF powdery feed containing 0.5% DCA only while the DCA and BF group (filled circle) was given MF powdery feed containing both 0.5% DCA and 5% BF. Values indicate mean ± SD (n = 6). *P < 0.05 against the respective control values. BF, Biofermentics™(lactic acid bacteria-fermented soybean extract); AST, l-asparate aminotransferase; ALT, l-alanine aminotransferase; DCA, deoxycholic acid (hepatopathy inducer).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2722200&req=5

Figure 1: Effects of oral BF administration on serum AST (A) and ALT (B) activities in rats with hepatic disorders induced by DCA loading. The DCA control group (open square) was given MF powdery feed containing 0.5% DCA only while the DCA and BF group (filled circle) was given MF powdery feed containing both 0.5% DCA and 5% BF. Values indicate mean ± SD (n = 6). *P < 0.05 against the respective control values. BF, Biofermentics™(lactic acid bacteria-fermented soybean extract); AST, l-asparate aminotransferase; ALT, l-alanine aminotransferase; DCA, deoxycholic acid (hepatopathy inducer).

Mentions: As shown in Fig. 1A, in the DCA-administered control group, serum AST activity rapidly increased to 786 ± 475 IUl at 2 weeks, reached its highest value of 2469 ± 2182 IU/l at 4 weeks, then sharply decreased to 722 ± 502 IU/l at 6 weeks. However, these rapidly increased activities were markedly lowered to 195 ± 105 IU/l, 788 ± 744 IU/l and 147 ± 67 IU/l at 2, 4 and 6 weeks, respectively, in the BF- and DCA- administered group. Thus, the increase of AST activity induced by DCA was clearly reduced by the administration of BF, with reductions significant (P < 0.05) at 2 and 6 weeks. Similarly, in the case of ALT, the increased activity found in controls was also depressed in the BF- administered group (Fig. 1B), with the value at 2 weeks significantly different (P < 0.05) from the DCA- administered control group.Figure 1.


Improvement of Experimentally Induced Hepatic and Renal Disorders in Rats using Lactic Acid Bacteria-fermented Soybean Extract (BiofermenticsTM).

Shin R, Suzuki M, Mizutani T, Susa N - Evid Based Complement Alternat Med (2007)

Effects of oral BF administration on serum AST (A) and ALT (B) activities in rats with hepatic disorders induced by DCA loading. The DCA control group (open square) was given MF powdery feed containing 0.5% DCA only while the DCA and BF group (filled circle) was given MF powdery feed containing both 0.5% DCA and 5% BF. Values indicate mean ± SD (n = 6). *P < 0.05 against the respective control values. BF, Biofermentics™(lactic acid bacteria-fermented soybean extract); AST, l-asparate aminotransferase; ALT, l-alanine aminotransferase; DCA, deoxycholic acid (hepatopathy inducer).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2722200&req=5

Figure 1: Effects of oral BF administration on serum AST (A) and ALT (B) activities in rats with hepatic disorders induced by DCA loading. The DCA control group (open square) was given MF powdery feed containing 0.5% DCA only while the DCA and BF group (filled circle) was given MF powdery feed containing both 0.5% DCA and 5% BF. Values indicate mean ± SD (n = 6). *P < 0.05 against the respective control values. BF, Biofermentics™(lactic acid bacteria-fermented soybean extract); AST, l-asparate aminotransferase; ALT, l-alanine aminotransferase; DCA, deoxycholic acid (hepatopathy inducer).
Mentions: As shown in Fig. 1A, in the DCA-administered control group, serum AST activity rapidly increased to 786 ± 475 IUl at 2 weeks, reached its highest value of 2469 ± 2182 IU/l at 4 weeks, then sharply decreased to 722 ± 502 IU/l at 6 weeks. However, these rapidly increased activities were markedly lowered to 195 ± 105 IU/l, 788 ± 744 IU/l and 147 ± 67 IU/l at 2, 4 and 6 weeks, respectively, in the BF- and DCA- administered group. Thus, the increase of AST activity induced by DCA was clearly reduced by the administration of BF, with reductions significant (P < 0.05) at 2 and 6 weeks. Similarly, in the case of ALT, the increased activity found in controls was also depressed in the BF- administered group (Fig. 1B), with the value at 2 weeks significantly different (P < 0.05) from the DCA- administered control group.Figure 1.

Bottom Line: In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of d-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF.Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group.These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

View Article: PubMed Central - PubMed

Affiliation: Central Institute for Health Science, A.L.A. Corporation 40-14 Kitamachi, Seya-ku, Yokohama-city, Kanagawa, 246-0002 Japan. rshin@ciala.co.jp.

ABSTRACT
The effects of lactic acid bacteria-fermented soybean extract (Biofermentics; BF) on experimental models of hepatic and renal disorders were investigated in vivo and in vitro. In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of d-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF. Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group. Pretreatment of primary cell cultures of rat hepatic and renal cells with BF prior to exposure to dichromate (K(2)Cr(2)O(7)) resulted in a marked decrease of dichromate-induced cytotoxicity as evaluated by the leakage of lactate dehydrogenase The levels of dichromate-induced lipid peroxidation, as monitored by malondialdehyde formation, were also reduced by pretreatment of hepatocytes with BF. These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

No MeSH data available.


Related in: MedlinePlus